Now

2019 is the year that gene therapies have come into their own. After decades of unfulfilled potential, this space is gaining tangible momentum, particularly in addressing the significant unmet need in a range of rare diseases.

Gene Therapy for Rare Disorders Europe is the uniquely focused conference uniting industry leaders to discuss the late-stage challenges that need to be overcome to deliver more gene therapies to market.

Rather than early stage basic science, this meeting is solely devoted to addressing the latest clinical, manufacturing, regulatory and commercialization challenges facing this rapidly evolving field. This is a comprehensive guide to define your commercial path forward.

Early booking and group discounts apply. Please visit the website for more information.

URL:
Brochure: https://go.evvnt.com/469888-3?pid=5731

Price
Conference + 2 Workshops - Book By Friday 2nd August: GBP 2997.0
Conference + 1 Workshop - Book By Friday 2nd August: GBP 2498.0
Conference Only - Book By Friday 2nd August: GBP 1999.0
1 Workshop Only: GBP 599.0

Artists / Speakers: Diego Ardigo, R&D Rare Diseases Unit Head, Chiesi & Chairman, Therapies Scientific Committee, IRDiRC, Rik Bleijs, Environmental Risk Assessor, Clinical Gene Therapy Trials, National Institute for Public Health and the Environment (RIVM), Pedro Campino, Global Regulatory Lead, Gene Therapy, CSL Behring, Jean-Philippe Combal, CEO, Vivet Therapeutics, Gavin Corcoran, Chief R&D Officer, Axovant Sciences, Nick Crabb, Programme Director, Scientific Affairs, NICE, Emily Culme-Seymour, Associate Director, Clinical Sciences, Sangamo Therapeutics, Andeleeb Dahy, Associate Director, Regulatory Affairs, Astellas, Marcus Droege, Global Head, RWE & Evidence, AveXis, a Novartis Company, Matthias Hebben, VP, Technology Development, Logicbio Therapeutics, Barrett Katz, CMO, GenSight Biologics, Tony Khoury, Vice President of Technical Services, Project Farma, Sven Kili, Principle, Sven Kili Consulting, Rune Kjeken, Scientific Director, Advanced Therapies, CAT, EMA, Mahesh Kudari, Program Leader, Clinical Development, Orchard Therapeutics, Ian McKay, Innovation Lead, Advanced Therapies, Innovate UK, Christeen Moburg, Senior Director, Patient Advocacy, Sangamo Therapeutics, Samantha Parker, SVP & Chief Patient Access Officer, Lysogene, Marcus Peters, Former CCO, Agilis Biotherapeutics, Lyndsey Scull, VP, Communications, Alliance for Regenerative Medicine (ARM), Aleš Strancar, CEO, BIA Separations, Jim Thomson, Senior Manager, Market Access & Gene Therapy, Pfizer, Birgitte Volck, President, R&D, AVROBIO, Speaker to be Confirmed, PPD Biotech